Comparative Pharmacology
Head-to-head clinical analysis: CALCIJEX versus VECTICAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CALCIJEX versus VECTICAL.
CALCIJEX vs VECTICAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Calcitriol, the active form of vitamin D, binds to the vitamin D receptor (VDR) in target tissues, increasing intestinal absorption of calcium and phosphate, promoting renal tubular reabsorption of calcium, and stimulating bone resorption. It also suppresses parathyroid hormone (PTH) synthesis and secretion via negative feedback.
VECTICAL (calcitriol) is a vitamin D analog that binds to vitamin D receptors (VDRs) in target tissues, increasing intestinal calcium absorption, renal calcium reabsorption, and enhancing osteoclast activity to mobilize calcium from bone, thereby raising serum calcium levels.
Intravenous: 0.5 mcg three times per week during dialysis; may be increased by 0.25-0.5 mcg at 2-4 week intervals. Oral: 0.25 mcg daily; may be increased to 0.5 mcg daily.
1-2 mcg orally twice daily, increased every 2-4 weeks based on serum calcium and PTH levels. Maximum dose: 4 mcg twice daily.
None Documented
None Documented
Terminal elimination half-life ranges from 5 to 10 hours in patients with normal renal function. In renal impairment, half-life may be prolonged up to 20 hours or more.
Mean terminal elimination half-life is approximately 3.7 hours (range 2.5–5.5 hours) in healthy adults. Clinically, steady-state is achieved within 2–3 days.
Primarily hepatic (biliary-fecal) elimination; approximately 2-4% excreted unchanged in urine. Small amount undergoes enterohepatic recirculation.
Primarily hepatobiliary (74%) and fecal (14%), with renal excretion accounting for <1% of the administered dose as unchanged drug. Enterohepatic recirculation occurs.
Category C
Category C
Vitamin D Analog
Vitamin D Analog